Brieflist

UKRI Translation: MRC Impact Acceleration Awards (Grant)

Apply to the MRC Impact Acceleration Award to address a single, high-risk development step and generate key data to de-risk a new medicine, medical device, diagnostic or other medical product.

Read the official page on Find a grant ↗Start an application ↗ Get new grants like this

Funder
UK Research and Innovation, Medical Research Council
Where
🇬🇧 United Kingdom
Status
Closes 10 Mar 2027 · 110 days left
Opened
12 Nov 2026
Funding
£50k–£300k per award (£1000m in total)
Who can apply
Most organisations
Topics
Health Science & research Innovation & technology

About this grant

Apply to the MRC Impact Acceleration Award for single-step support in developing a new or repurposed medicine, medical device, diagnostic, or other medical product.

Projects must target a high-risk development step backed by prior funding, generating critical data to de-risk onward progression or determine failure.

The MRC Impact Acceleration Award strategically bridges the smaller Impact Acceleration Account (IAA) and the larger MRC Proof of Concept funding opportunity.

You must be based at a research organisation eligible for MRC funding.

This funding opportunity was formerly known as ‘Gap Fund: single-step support for medical product development’.

Objectives

Demand management

Demand management is being applied to this funding opportunity. Further details are provided in the ‘who can apply’ section

Scope

You can apply for academically led translational projects that aim to undertake a single-step package of development work that will bridge the gap between the inception of a new idea and substantive funding through schemes such as the MRC Proof of Concept funding opportunity (formerly Developmental Pathway Funding Scheme, DPFS).The MRC Impact Acceleration Award supports our strategic priorities including:

precision prevention to reduce disease risk in targeted populations

early and accurate diagnosis to improve speed and accuracy of disease detection

advanced treatments offering novel therapeutic approaches

improve outcome monitoring of patients receiving treatment

better management of diseases and conditions through innovative technologies

All human diseases and medical interventions are eligible for support, both in the context of UK healthcare and addressing global health issues.You should note the MRC Impact Acceleration Award will only support single-step projects, focusing on one goal rather than multiple steps. We recommend requesting only the funding needed for this specific goal, unless applying for the maximum amount is scientifically justified.Your project should have already explored a new concept and generated some data in support of the approach. Your application should clearly articulate:

the core concept of the project

the critical one-step gap that needs to be addressed

an explanation of how the proposed plan will address this critical gap

the challenges and issues involved in onward development

This fund will provide small scale funding to generate critical data needed prior to seeking more substantive funding. A non-exhaustive list of examples of the types of projects that could be supported include:

high-risk elements of therapeutic discovery, quantification and validation

high-risk stages of prototype development

early prototype testing

initial biomarker validation

vector identification or optimisation

hit expansion medicinal chemistry

In exceptional circumstances, you can submit follow on applications where you can justify the need for continued support. However, in most cases a positive outcome of the proposed work should be sufficient to allow submission of a longer and larger application, potentially to the MRC Proof of Concept funding opportunity.For more information on the background of this funding opportunity, go to the ‘Additional information’ section.Applications from research organisations who are not recipients of an Impact Acceleration Account may use this funding opportunity to apply for more preliminary studies. The scale and scope of the request should reflect a project more in line with earlier stages of development.You should highlight within the application that you are applying for an IAA-like project and that your research organisation does not provide this opportunity.

Activities we support

You can apply for funding for work on novel:

new small molecule medicines

vaccines for infectious or non-infectious disease

biologics (antibodies, peptides, proteins)

advanced therapeutics (for example, gene therapy, cell therapy, RNA therapy, nucleic acid therapy and T-cell therapy)

complex medicines for example PROTACS, molecular glues and antibody-drug conjugates

regenerative medicine approaches

repurposing clinical studies or using existing therapies for new indications

medical devices

digital healthcare and app development

diagnostics (including biomarker validation but excluding biomarker identification)

medical imaging technology

surgical techniques or tools

behavioural and psychological interventions

radiotherapy and radiation protocols

We note that many applications in each of these categories may include artificial intelligence (AI) methodologies. A significant use of AI in an MRC Impact Acceleration …

Dates

Assessment process

We will assess your application using the following process.

Your application will be assessed by members of the MRC Proof of Concept panel with additional expertise sourced as necessary.

We will not obtain any external expert review comments as part of the assessment process.

For more information on how we prioritise applications for funding please visit How we make decisions.

Timescale

We aim to complete the assessment process within 12 weeks of the application closing date.

Feedback

Outcomes will be communicated within 10 working days of the panel meeting.

Feedback will be provided within eight to 10 weeks of the panel meeting.

Principles of assessment

We support the San Francisco declaration on research assessment and recognise the relationship between research assessment and research integrity.

Find out about the UKRI principles of assessment and decision making.

Using generative artificial intelligence (AI) in expert review

Generative AI may only be used for the purpose of language refinement during application assessment. When using generative AI to refine the language of a review, expert reviewers and panellists must ensure that:

no part of the application being assessed is entered into a generative AI tool

no personal information from the application is disclosed

generative AI is not tasked with understanding, summarising or evaluating the application’s content

Expert reviewers and panellists must also:

comply with relevant intellectual property and data protection legislation

not take into account or speculate within their assessment whether generative AI has been used to develop the application

For more detail see our policy on the use of generative AI.

We reserve the right to modify the assessment process as needed.

Assessment areas

The assessment areas we will use are:

background to the application

approach

applicant and team capability to deliver

intellectual property rights (IPR)

resources and costs

ethics and responsible research and innovation (RRI)

data management and sharing

Find details of assessment questions and criteria under the ‘Application questions’ heading in the ‘How to apply’ section.

The panel will assess your application based on the following areas:

clinical or medical need: whether the need is significant and whether the application has an advantage over competing solutions

rationale: the strength of the scientific rationale and perceived likelihood that the proposed solution will meet the targeted need

deliverability: whether the team has access to the necessary expertise and support to deliver the planned work. Whether the project is designed to generate the right data to progress to the next stage and more substantive funding. Whether the future development plan is realistic, and whether the solution is likely to address the need identified

intellectual property: whether there is an appropriate intellectual property strategy in place to facilitate downstream development, clinical uptake or commercialisation

The panel is keen to support high risk projects, as long as the project plan is designed to enable a clear decision on the suitability of the intervention for onward translation, at the end of this phase of funding. Translational projects are inherently risky and therefore a ’failure rate’ of 50% is expected in relation to projects supported.

Projects with no clear and plausible development plan of their proposed route to market or patient benefit after this award are unlikely to be supportable.

Projects with multiple goals and work packages, that do not address a single high-risk evidence gap are unlikely to be supportable.

The decisions of the MRC Proof of Concept panel will not be open to appeal.

See the MRC Proof of Concept panel.

Webinar for potential applicants

We held a webinar on 16 June 2025. This provided more information about the funding opportunity and a chance to ask questions.

Watch the webinar (YouTube)

Eligibility

Find out if you can apply for funding.

This funding opportunity is open to organisations with standard eligibility. Check if your organisation is eligible.

Who is eligible to apply

This funding opportunity is open to applicants who meet the individual eligibility criteria.

To be eligible to apply for this funding opportunity you must:

show that you will direct the project and be actively engaged in the work

be looking to generate critical preliminary data to build confidence in the development strategy for a new medicine, repurposed medicine, medical device, diagnostic test, or other medical intervention development

For applicants who do not have a contract of employment for the duration of the proposed project, by submitting an application the research organisation is confirming, if it is successful:

contracts will be extended beyond the end date of the project

all necessary support for you and the project will be provided, including mentorship and career development for early career researchers

Demand management

You can only submit one application as project lead to this funding opportunity.

Who is not eligible to apply

You are not eligible to apply for this funding opportunity as a project lead if you are based at an international research organisation. This does not include the MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine (LSHTM) or MRC/UVRI (Uganda Virus Research Institute) and LSHTM Uganda Research Unit.

If you are employed by these organisations you cannot apply as project lead or project co-lead, but can participate as project partners on an application led by an eligible UK organisation:

businesses

charity and third sector organisations

However, charities and third sector organisations that are approved UKRI Independent Research Organisations are eligible to apply as project lead or project co-lead.

International researchers

As MRC is a lead funder for this funding opportunity, international researchers can apply as ‘project co-lead (international)’. You should include all other international collaborators (or UK partners not based at approved organisations) as project partners.

Project co-leads (international) make a major intellectual contribution to the design or conduct of the project. Their contribution and added value to the research collaboration should be clearly explained and justified in the application, see ‘Applicant and team capability to deliver’.

Read the UKRI project co-lead …

Applying for grants? Grants Pro e-mails you every morning with the new grants and opened forecasts that match your saved searches, and adds deadline reminders in your calendar, a private RSS feed and CSV export. Try it free for 7 days, then $9/month, cancel any time. See what Pro does →

Applying? Read how to write a winning grant proposal.

Contains public sector information licensed under the Open Government Licence v3.0 (Find a grant). Last checked 19 Nov 2026. Always read the official page before applying: it has the full conditions, documents and how to apply.

Similar grants

Gambling harms research grants (Grant)

UK Research and Innovation, Arts and Humanities Research Council, Medical Research Council, Economic and Social Research Council, Biotechnology and Biological Sciences Research Council · UK · £1–£2m

Closes 8 Dec 2026 · 18 days left Most organisations

Condition Improvement Fund (CIF)

Department for Education · UK · £20k–£4m

Closes 15 Dec 2026 · 25 days left Nonprofits & charities Universities & schools Public bodies